Biomarin Pharmaceutical BMRN is set to give its latest quarterly earnings report on Monday, 2023-02-27. Here's what investors need to know before the announcement. Analysts estimate that Biomarin Pharmaceutical will report an earnings per share (EPS) of $-0.07.  Biomarin Pharmaceutical bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Last quarter the company missed EPS by $0.03, which was followed by a 6.92% drop in the share price the next day. Here's a look at Biomarin Pharmaceutical's past performance and the resulting price change: 


Quarter
Q3 2022
Q2 2022
Q1 2022
Q4 2021




EPS Estimate
-0.01
0.11

-0.32


EPS Actual
-0.04
0.59
0.17
-0.32


Price Change %
-6.92%
5.18%
2.9%
-6.27%


 Shares of Biomarin Pharmaceutical were trading at $103.18 as of February 23. Over the last 52-week period, shares are up 30.98%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.  To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar on our site. This article was generated by Benzinga's automated content engine and reviewed by an editor. Â© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. Sort by estimates, projected upside, profit surprises, and more to easily find new stocks to invest in or check up on your portfolio. Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.